Autopsy report · NCT00040768

Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Administratively complete.”

The sponsor’s own words in the registry.

Life of this trial

Registered 3 months after it had already started.
35 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: National Cancer Institute (NCI)
Sponsor type: US National Institutes of Health
Conditions: Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: bortezomib
Participants: 35
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.